期刊文献+

超敏C反应蛋白检测在冠心病诊断中的临床价值探讨

To Explore the Clinical Value of HS-CRP Detection in Diagnosis of Coronary Heart Disease
下载PDF
导出
摘要 目的探讨超敏C反应蛋白(HS-CRP)检测在冠心病(CHD)诊断中的应用价值。方法结合临床检查及冠脉造影情况,将180例冠心病患者分为稳定性心绞痛(SAP)、不稳定性心绞痛(UAP)、急性心肌梗死(AMI)3个组,分别测定180例冠心病患者血清超敏C反应蛋白(HS-CRP)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB),并与80例健康人做对比。结果与正常对照组比较,CHD组血清HS-CRP均升高,P<0.05,差异具有统计学意义,且AMI组血清的HS-CRP浓度高于UAP组,P<0.05,差异具有统计学意义,UAP组血清的Hs-CRP浓度高于SAP组,P<0.05,差异具有统计学意义,且AMI组治疗后HS-CRP浓度下降,冠心病阳性检出率HS-CRP(90.0%)>CK(35.6%)>CK-MB(38.3%)。结论血清HS-CRP水平高低与CHD病情密切相关,可作为冠心病患者病情严重程度的敏感性指标。 Objective To explore the clinical diagnostic value of the determination of serum HS-CRP.Methods Combined with clinical examination and coronary angiography,180 cases of coronary heart disease were divided into three groups,including stable angina pectoris group, unstable angina pectoris group and acute myocardial infarction group, HS-CRP, CK and CK-MB were parallelly detected and performed the comparative analysis in 180 cases of observation group and 80 cases of healthy control group.Results Compared with the healthy control group,the serum HS-CRP in CHD groups was significantly increased,P〈0.05, had difference statistically significance, the serum HS-CRP in AMI group was higher than that in UAP group,P〈0.05, had difference statistically significance, the serum HS-CRP in UAP group was significantly higher than that of group SAP,P〈0.05, had difference statistically significance, the serum HS-CRP in the AMI group after treatment has decreased significantly,the positive rate in CHD groups was HS-CRP (90.0%)〉CK(35.6%)〉CK-MB(38.3%).Conclusion It is suggested that the serum HS-CRP level is closely correlated with severity degree of the coronary heart disease,may be used as sensitive indexes of the severity of illness in patients with coronary heart disease.
作者 田育佼
出处 《中国继续医学教育》 2015年第29期43-44,共2页 China Continuing Medical Education
关键词 超敏C反应蛋白 冠心病 HS-CRP Coronary heart disease
  • 相关文献

参考文献3

二级参考文献34

  • 1[1]Ross R. Atherosclerosis-an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
  • 2[2]Ledue TB, Rifai N. High sensitivity immunoassays for C-reactive protein: promises and pitfalls[J]. Clin Chem Lab Med, 2001, 39(11):1171-1176.
  • 3[3]Whicher J, Rifai N, Biasucci LM. Markers of the acute phase response in cardiovascular disease: an update[J].Clin Chem Lab Med, 2001, 39(11):1054-1064.
  • 4[4]Rifai N, Ridker PM. High-sensitivity C-reactive protein:a novel and promising marker of coronary heart disease [J]. Clin Chem, 2001,47(3):403-411.
  • 5[5]Morley JJ, Kushner I. Serum C-reactive protein levels in disease[J]. Ann N Y Acad Sci, 1982,389:406-418.
  • 6[8]Rothkrantz-Kos S, Schmitz MP, Bekers O, et al. Highsensitivity C-reactive protein methods examined[J]. Clin Chem, 2002,48(2): 359-362.
  • 7[9]Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina [J]. Circulation, 1999,100 (19):1958-1963.
  • 8[10]Morrow DA, Rifai N, Antman EM, et al. C-Reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy[J]. J Am Coll Cardiol ,1998; 31(7): 1460 -1465.
  • 9[11]de Winter RJ, Bholasingh R, Lijmer JG, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction[J]. Cardiovasc Res, 1999,42 (1):240-245.
  • 10[12]Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group [J]. Lancet ,1997, 349(9050): 462-466.

共引文献146

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部